Moberg Sells Consumer Health Portfolio To Pay For Focusing On Rx Research
Moberg had been expanding its OTC topical and nutritional supplement portfolio while also continuing trials for Rx ingredients including its MOB-015 formulation of terbinafine indicated for fingernail and toenail fungus. But $155m agreement with two investment groups will complete Moberg's divestment of consumer health brands and make it dedicated to R&D, regulatory matters and business development.
You may also be interested in...
RoundTable Healthcare Partners establishes Everwell Health Holdings for investing in consumer health and wellness functional ingredient businesses; Nutrition21 is Everwell’s first investment.
Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.
Sweden’s Moberg Pharma is to launch its Emtrix fungal nail product across the Middle East and Africa after signing an agreement with Mundipharma.